Neuronetics, Inc.

Neuronetics, Inc. is a medical technology company specializing in neurohealth solutions and transcranial magnetic stimulation (TMS) therapy. Its flagship product is the NeuroStar Advanced Therapy System, an FDA-cleared, non-invasive office-based platform designed to treat major depressive disorder, obsessive-compulsive disorder, and anxious depression. The company sells these therapy systems, recurring treatment sessions, warranties, and practice management tools to healthcare providers, primarily targeting psychiatrists along with primary care physicians and pain management specialists. Additionally, through its subsidiary Greenbrook, it operates mental health centers that deliver TMS procedures and SPRAVATO nasal spray treatments.

The company distributes its products in the United States and selected international markets, including Japan and the European Union. Its operations include a network of 93 treatment centers across 15 U.S. states and support from 658 employees as of year-end 2025. Neuronetics manages product supply and operations from Malvern, Pennsylvania.

Summary of the business section of Neuronetics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 658 full-time employees working collaboratively across our sales and customer support team, in research and development, including clinical, regulatory and certain quality functions, operations and in general and administrative.”